UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)
Phase 1
Completed
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT01449071
- Locations
- 🇯🇵
09, Fukuoka, Japan
🇯🇵10, Fukuoka, Japan
🇯🇵11, Fukuoka, Japan
Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1250
- Registration Number
- NCT01408576
- Locations
- 🇺🇸
539, Birmingham, Alabama, United States
🇺🇸557, Little Rock, Arkansas, United States
🇺🇸515, Hemet, California, United States
Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy
Phase 3
Completed
- Conditions
- Epilepsy
- Interventions
- First Posted Date
- 2011-07-29
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 105
- Registration Number
- NCT01405508
- Locations
- 🇺🇸
001, Phoenix, Arizona, United States
🇺🇸775, Little Rock, Arkansas, United States
🇺🇸780, Lexington, Kentucky, United States
An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures
- First Posted Date
- 2011-07-21
- Last Posted Date
- 2017-08-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 44
- Registration Number
- NCT01398956
- Locations
- 🇯🇵
152, Fujisawa, Japan
🇯🇵112, Fukuoka, Japan
🇯🇵113, Fukuoka, Japan
Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese Subjects
- First Posted Date
- 2011-07-14
- Last Posted Date
- 2011-10-06
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 25
- Registration Number
- NCT01394224
Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation
Completed
- Conditions
- Restless Legs Syndrome
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 102
- Registration Number
- NCT01386944
- Locations
- 🇩🇪
12, Berlin, Germany
🇩🇪4, Bremen, Germany
🇩🇪18, Dresden, Germany
Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 11
- Registration Number
- NCT01375374
- Locations
- 🇦🇹
11, Innsbruck, Austria
🇦🇹12, Salzburg, Austria
🇩🇪2, Bielefeld, Germany
Three-way-cross-over Study to Evaluate Safety and Pharmacokinetics of Lacosamide in Healthy Japanese and Chinese Males
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 33
- Registration Number
- NCT01375387
Open-label Long-term Study of Adjunctive Brivaracetam in Pediatric Subjects With Epilepsy
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- UCB Pharma SA
- Target Recruit Count
- 257
- Registration Number
- NCT01364597
- Locations
- 🇺🇸
N01266 243, Los Angeles, California, United States
🇺🇸N01266 108, Gulf Breeze, Florida, United States
🇺🇸N01266 103, Wellington, Florida, United States
Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations
- First Posted Date
- 2011-04-20
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 56
- Registration Number
- NCT01338896